Morphic Announces Initiation of EMERALD-2 Phase IIb Clinical Trial of MORF-057 in Patients with Moderate-to-Severe Ulcerative Colitis

Morphic Therapeutic announced that the EMERALD-2 phase IIb study of MORF-057 in ulcerative colitis had commenced with the first patient receiving MORF-057.